>>
Portada > Principal Equip > Enriqueta Felip

INVESTIGADORS PRINCIPALS

Enriqueta Felip
ENRIQUETA FELIP

ENRIQUETA FELIP

Llocs de treball actuals

  • Cap del Programa de càncer de pulmó
  • Metgessa especialista en oncologia mèdica a l'Hospital Universitari Vall d'Hebron
  • Cap del Servei d'Oncologia Mèdica del Comitè de Tumors Toràcics de l'Hospital Vall d'Hebron des de 1995.
  • Coordinadora europea de la Secció de Suport de les Directrius de la Societat Europea d'Oncologia Mèdica des de 2001
  • Membre del Comitè Executiu del Grup Espanyol de Càncer de Pulmó (GECP)
  • Membre de la Junta Directiva de la Societat Espanyola d'Oncologia Mèdica (SEOM)
  • Representant espanyola de la Societat Europea d'Oncologia Mèdica (ESMO)
  • Membre actiu de l'Associació Internacional per a l'Estudi del Càncer de Pulmó (IASLC)

Titulacions acadèmiques

  • Llicenciada en medicina i cirurgia per la Universitat Autònoma de Barcelona, 1987
  • Doctora en medicina i cirurgia per la Universitat Autònoma de Barcelona, 1994

Àrees de recerca

  • Optimització dels tractaments multidisciplinaris
  • Integració primerenca dels determinants genètics per a personalitzar els tractaments
  • Desenvolupament de nous fàrmacs

Premis i beques

Publicacions científiques més rellevants

  • Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K,
    Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.
    Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced
    ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol.
    2016 Aug 20;34(24):2858-65.
  • Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL,
    Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P,
    Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III Randomized Trial of
    Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum
    in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 Jul 25. pii:
    JCO676601. [Epub ahead of print]
  • Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A,
    Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Analysis of expression
    of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant
    pleural mesothelioma (MPM). Lung Cancer. 2016 Jun;96:1-6.
  • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH,
    Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM,
    Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for
    previously treated, PD-L1-positive, advanced non-small-cell lung cancer
    (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr
    9;387(10027):1540-50. 
  • Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015 Aug; 26(8): 1573-88
  • Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol 2015 Jun; 10(2): 255-65
  • Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015 Feb; 17(2): 103-12
  • Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015 Jun; 21(6): 560-2
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr; 372(18): 1689-99
  • Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, Lopez-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 2015; 5: 17499

Totes les publicacions

  • Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csoszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR; KEYNOTE-024 Investigators. 2016. N Engl J Med. 375: 1823-1833. IF:59,558
  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB. 2016. Lancet. 387: 1540-1550. IF:44,002
  • TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM. 2016. Lancet Oncol. 17: 212-223. IF:26,509
  • Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT. 2016. Lancet Oncol. 17: 452-463. IF:26,509
  • Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014.Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS. 2016. J Clin Oncol. 34: 2858-2865. IF:20,982
  • Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2.Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT. 2016. J Clin Oncol. 34: 2866-2873. IF:20,982
  • Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer.Reck, Martin; Luft, Alexander; Szczesna, Aleksandra; Havel, Libor; Kim, Sang-We; Akerley, Wallace; Pietanza, Maria Catherine; Wu, Yi-long; Zielinski, Christoph; Thomas, Michael; Felip, Enriqueta; Gold, Kathryn; Horn, Leora; Aerts, Joachim; Nakagawa, Kazuhiko; Lorigan, Paul; Pieters, Anne; Sanchez, Teresa Kong; Fairchild, Justin; Spigel, David. 2016. J Clin Oncol. 34: 3740-3748. IF:20,982
  • Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial.Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D; LUX-Lung 5 Investigators. 2016. Ann Oncol. 27: 417-423.IF:9,269
  • Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø. 2016. Ann Oncol. 27: 1291-1298. IF:9,269
  • 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials..Felip E; Crinò L; Kim DW; Spigel DR; Nishio M; Mok T; Scagliotti G; Cesic D; Sutradhar S; Shaw AT. 2016. J Thorac Oncol. IF:5,040
  • 178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC..Tan D; Liu G; Kim DW; Thomas M; Felip E; Signorovitch J; Zhang J; Szczudlo T; Shaw AT. 2016. J Thorac Oncol. IF:5,040
  • 193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received =1 prior systemic treatment..Felip E; Van Meerbeeck J; Wolf J; Ardizzoni A; Li A; Srinivasan S; Popat S. 2016. J Thorac Oncol. IF:5,040
  • Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC.Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Arez LP; Chouaid C; Rosell R; GECP; AIOT and GFPC groups. 2016. J Thorac Oncol. 11: 801-807. IF:5,040
  • MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology..Shaw AT; Spigel DR; Tan DS; Kim DW; Mehra R; Orlov S; Park K; Yu CJ; Mok T; Nishio M; Scagliotti G; Sutradhar S; Cesic D; Felip E. 2016. J Thorac Oncol. IF:5,040
  • ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology..Wakelee H; Patel JD; Heist R; Balmanoukian A; Besse B; Felip E; Carcereny Costa E; Chow LQ; Koczywas M; Garassino MC; Christoph D; Toh CK; Johnson ML; Chaft J; Kurata T; Qiu J; Kowanetz M; Coleman S; Mocci S; Sandler A; Gettinger SN; Peters S. 2016. J Thorac Oncol. IF:5,040
  • ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016..Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz JP; Österlund P; Pavlidis N; Purkalne G; ESMO/ASCO Global Curriculum Working Group. 2016. Ann Oncol. 27: 1378-1381. IF:9,269
  • P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy..Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; Surmont V; De Castro G; Garrido M; Shentu Y; Dolled-Filhart M; Im E; Garon EB. 2016. J Thorac Oncol. IF:5,040
  • P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy..Ramalingam S; Hui R; Gandhi L; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Leighl N; Aggarwal C; Horn L; Patnaik A; Middleton GW; Gubens M; Hellmann M; Soria JC; Lubiniecki GM; Zhang J; Piperdi B; Garon EB. 2016. J Thorac Oncol. IF:5,040
  • P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy..Borghaei H; Brahmer J; Horn L; Ready N; Steins M; Felip E; Paz-Ares L; Xx X; Barlesi F; Antonia S; Fayette J; Rizvi N; Crino L; Reck M; Erich Eberhardt WE; Hellmann M; Desai K; Li A; Healey D; Spigel D; Mathias C. 2016. J Thorac Oncol. IF:5,040
  • PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment..Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; Surmont V; De Castro G; Garrido M; Shentu Y; Dolled-Filhart M; Im E; Garon EB. 2016. J Thorac Oncol. IF:5,040
  • PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology..Gordon MS; Herbst RS; Horn L; Soria JC; Gandhi L; Felip E; Sequist L; Spigel DR; Antonia SJ; Balmanoukian A; Cassier P; Liu B; Kowanetz M; O'Hear C; Fassò M; Sandler A; Gettinger SN. 2016. J Thorac Oncol. IF:5,040
  • PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology..Vallieres E; Felip E; Altorki N; Zhou C; Zuo Y; Howland M; Xia F; Hoang T; Sandler A; Wakelee H. 2016. J Thorac Oncol. IF:5,040
  • The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma..Rice D; Chansky K; Nowak A; Pass H; Kindler H; Shemanski L; Opitz I; Call S; Hasegawa S; Kernstine K; Atinkaya C; Rea F; Nafteux P; Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advis. 2016. J Thorac Oncol. 11: 2100-2111. IF:5,040
  • The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation..Pass H; Giroux D; Kennedy C; Ruffini E; Cangir AK; Rice D; Asamura H; Waller D; Edwards J; Weder W; Hoffmann H; van Meerbeeck JP; Nowak A; Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participatin. 2016. J Thorac Oncol. 11: 2082-2088. IF:5,040
  • The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.Nowak AK; Chansky K; Rice DC; Pass HI; Kindler HL; Shemanski L; Billé A; Rintoul RC; Batirel HF; Thomas CF; Friedberg J; Cedres S; de Perrot M; Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Inst. 2016. J Thorac Oncol. 11: 2089-2099. IF:5,040
  • The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Rusch VW; Chansky K; Kindler HL; Nowak AK; Pass HI; Rice DC; Shemanski L; Galateau-Sallé F; McCaughan BC; Nakano T; Ruffini E; van Meerbeeck JP; Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participati. 2016. J Thorac Oncol. 11: 2112-2119. IF:5,040
  • Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E. 2016. Lung Cancer. 96: 1-6. IF:3,767
  • A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M. 2016. Lung Cancer. 99: 94-101. IF:3,767
  • Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F. 2016. Expert Opin Biol Ther. 16: 1479-1489. IF:3,438
  • The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F. 2016. CLIN LUNG CANCER. 17: 161-168. IF:3,030
  • Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies.Planchard D; Brown KH; Kim DW; Kim SW; Ohe Y; Felip E; Leese P; Cantarini M; Vishwanathan K; Jänne PA; Ranson M; Dickinson PA. 2016. Cancer Chemother Pharmacol. 77: 767-776. IF:2,824
  • Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07.Isla D; Felip E; Viñolas N; Provencio M; Majem M; Artal A; Bover I; Lianes P; DE Las Peñas R; Catot S; DE Castro J; Blasco A; Terrasa J; Gonzalez-Larriba JL; Juan O; Dómine M; Bernabe R; Garrido P. 2016. Anticancer Res. 36: 6647-6653. IF:1,895
  • Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.Gamarra, F.; Noël, J.-L.; Brunelli, A.; Dingemans, A.-M.C.; Felip, E.; Gaga, M.; Grigoriu, B.D.; Hardavella, G.; Huber, R.M.; Janes, S.; Massard, G.; Putora, P.M.; Sculier, J.-P.; Schnabel, P.A.; Ramella, S.; Van Raemdonck, D.; Meert, A.-P.. 2016. Breathe. 12: 249-255.
  • ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz JP; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EG; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AW; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne CH; Kunstfeld R; Lenz HJ; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll HJ; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y. 2016. ESMO Open.
  • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016 Apr; 387(10027): 1540-50
  • Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015 Aug; 26(8): 1573-88
  • Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol 2015 Jun; 10(2): 255-65
  • Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015 Feb; 17(2): 103-12
  • Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015 Jun; 21(6): 560-2
  • De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr; 372(18): 1689-99
  • Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, Lopez-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 2015; 5: 17499
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015 Oct; 373(17): 1627-39
  • Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, García-Gómez R, Massuti B, Sanchez JM, Porta R, Ponce-Aix S, Morán T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol 2015 May; 1(2): 149-57
  • Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug; 16(8): 897-907
  • Vansteenkiste JF, Canon JL, Braud FD, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol 2015 Sep; 10(9): 1319-27
  • Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015 May; 372(21): 2018-28
  • Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martínez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 2015; 10(3): e0121071
  • Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer 2015 Feb; 87(2): 89-95
  • Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
  • Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sánchez MJ. Lung cancer in women: an overview with special focus on Spanish women. Clin Transl Oncol 2014 Jun; 16(6): 517-28
  • Martínez P, Martinez-Marti A, Navarro A, Cedrés S, Felip E. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate? Lung Cancer 2014 May; 84(2): 97-100
  • Janne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martínez P, Felip E. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 2014 Mar; 9(3): 316-23
  • Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin. Cancer Res. 2014 Apr; 20(7): 2001-10
  • Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann. Oncol. 2014 Aug; 25(8): 1475-84
  • Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014 Mar; 370(13): 1189-97
  • Peghin M, Ruiz-Camps I, Garcia-Vidal C, Cervera C, Andreu J, Martín M, Gavaldá J, Gudiol C, Moreno A, Felip E, Pahissa A. Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. J. Infect. 2014 Oct; 69(4): 387-95
  • Martínez P, Sales Fidalgo PA, Felip E. Ganitumab for the treatment of small-cell lung cancer. Expert Opin Investig Drugs 2014 Oct; 23(10): 1423-32
  • Morán T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Exp Hematol Oncol 2014; 3(1): 26
  • Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014 Nov; 9(11): 1675-84
  • Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014 Dec; 371(23): 2167-77
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013 Oct; 24 Suppl 6: vi89-98
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013 Nov; 3(11): 1238-44
  • Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 2013 Dec; 8(12): 1529-37
  • Cedrés S, Montero MA, Zamora E, Martínez A, Martínez P, Fariñas L, Navarro A, Torrejón D, Gabaldon A, Ramón y Cajal S, Felip E. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. Clin Transl Oncol 2013 Dec;
  • Gamarra F, Boffetta P, De Ruysscher D, Felip E, Gaga M, Grigoriu B, Huber RM, Janes SM, Marquette CH, Massard G, Noel JL, Sculier JP, Meert AP. Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe. Eur. Respir. J. 2013 Sep; 42(3): 568-71
  • Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 2013 Dec; 82(3): 375-82
  • Camps C, Felip E, Garcia-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol 2013 Dec; 15(12): 977-84
  • Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013 Oct; 24 Suppl 6: vi99-105
  • Reeder-Hayes K, Felip E, Patt D, Jaffee E. Women in oncology: progress, challenges, and keys to success. Am Soc Clin Oncol Educ Book 2013; : 448-55
  • Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013 Jun; 31(16): 1997-2003
  • Cedrés S, Fariñas L, Stejpanovic N, Martínez P, Martínez A, Zamora E, Montero MA, Felip E. Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. J Thorac Dis 2013 Apr; 5(2): E35-7
  • Martínez P, Hernandez-Losa J, Montero MA, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodríguez-Freixinos V, Canela M, Ramón y Cajal S, Felip E. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE 2013; 8(1): e52261
  • Felip E, Martinez-Marti A, Martínez P, Cedrés S, Navarro A. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol 2013 Mar; 25(2): 115-20
  • Soria JC, Baselga J, Hannah A, Felip E, Calvo E, Armand JP, Harbison CT, Park JG, Zhang J, Pathak H, Herbst RS. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013 May; 49(8): 1815-24
  • Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012 Oct; 23 Suppl 7: vii83-5
  • Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012 Oct; 23 Suppl 7: vii56-64
  • Felip E, Martínez P. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers? Ann. Oncol. 2012 Sep; 23 Suppl 10: x189-92
  • Cedrés S, Torrejón D, Martínez A, Martínez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012 Nov; 14(11): 864-9
  • Felip E, Martinez-Marti A. DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma? Ann. Oncol. 2012 Sep; 23(9): 2211-4
  • Felip E, Ranson M, Cedrés S, Dean E, Brewster M, Martínez P, McNally V, Ross G, Galdermans D. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2012 Nov; 13(6): 432-41
  • Cedrés S, Mulet-Margalef N, Montero MA, Martínez P, Martínez A, Felip E. Rectal metastases from squamous cell carcinoma: a case report and review of the literature. Case Rep Med 2012; 2012: 947524
  • Cedrés S, Montero MA, Martínez P, Martínez A, Rodríguez-Freixinos V, Torrejón D, Gabaldon A, Salcedo M, Ramón y Cajal S, Felip E. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012 Jul; 77(1): 192-8
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, García-Gómez R, Pallarés C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Morán T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jiménez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sánchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3): 239-46
  • Martínez P, Felip E. Brain metastases: the need for a more tailored approach in non-small-cell lung cancer patients. Clin Transl Oncol 2012 Jan; 14(1): 1-2
  • Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012 Feb; 6(1): 15-26
  • Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 2012 Jan; 7(1): 203-11
  • Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Taron M, Santarpia MC, Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011 Feb; 71(2): 191-8
  • Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, Felip E. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann. Oncol. 2011 Sep; 22(9): 1973-80
  • Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011 Dec; 74(3): 544-8
  • Carbone DP, Felip E. Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer 2011 Sep; 12(5): 261-71
  • Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011 Sep; 11(9): 1223-31
  • Cedrés S, Nuñez I, Longo M, Martínez P, Checa E, Torrejón D, Felip E. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011 May; 12(3): 172-9
  • Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann. Oncol. 2011 Jul; 22(7): 1507-19
  • Dienstmann R, Martínez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011 Mar; 2(3): 165-77
  • Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 2011 Oct; 74(1): 1-6
  • Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J. Clin. Oncol. 2010 Jul; 28(19): 3131-7
  • Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sanchez JJ, Hermosilla E, Massuti B. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2010 Jul; 28(19): 3138-45
  • Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, Au JS, Felip E, Yang PC, Damyanov D, Orlov S, Akimov M, Delmar P, Essioux L, Hillenbach C, Klughammer B, McLoughlin P, Baselga J. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann. Oncol. 2010 Feb; 21(2): 217-22
  • Reck M, Frickhofen N, Cedrés S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010 Nov; 70(2): 180-7
  • Crinò L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v103-15
  • D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v116-9
  • Stahel RA, Weder W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v126-8
  • Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v184-6
  • Chan AT, Grégoire V, Lefebvre JL, Licitra L, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v187-9
  • Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009 Nov; 66(2): 257-61
  • Muñoz E, Cedrés S, Felip E. Rare tumours of the chest. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 400-1
  • Felip E, Garrido P, Trigo JM, López-Brea M, Paz-Ares L, Provencio M, Isla D. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2009 May; 11(5): 284-9
  • Sørensen M, Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009 May; 20 Suppl 4: 71-2
  • Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedrés S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U, Baselga J. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin. Cancer Res. 2008 Jun; 14(12): 3867-74
  • Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii81-2
  • Pivot X, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii79-80
  • Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii43-4
  • D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii39-40
  • Briasoulis E, Pavlidis N, Felip E. Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii106-7
  • Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2007 Apr; 18 Suppl 2: ii32-3